Vera Therapeutics shares surge 69% at open, marking largest gain since 2021.

Vera Therapeutics shares surge 69% at open, marking largest gain since 2021.

Vera Therapeutics, Inc. (NASDAQ: VERA) saw its shares surge by 69% at the market open on June 2, 2025, marking the largest gain since 2021. The significant increase in stock price comes on the heels of positive topline results from the ongoing Phase 3 ORIGIN study, which is testing atacicept for the treatment of immunoglobulin A nephropathy (IgAN).

According to the firm H.C. Wainwright, the drug atacicept demonstrated a 46% reduction in urine protein creatinine ratio from the baseline, leading to a statistically significant 42% reduction compared to a placebo group by week 36. These findings reinforce atacicept’s potential as a leading treatment for IgAN, suggesting it could become the best-in-class option for this condition [1].

The positive results have been a critical driver for Vera Therapeutics' stock movement. The company plans to engage with the FDA in the coming weeks to discuss the trial results and the regulatory pathway forward. The goal is to submit a Biologics License Application (BLA) for accelerated approval in the fourth quarter of 2025, with a potential commercial launch in the United States in 2026 [3].

Wall Street analysts have also shown optimism. Evercore ISI analysts maintained an Outperform rating for Vera Therapeutics stock, with a price target of $75.00. The analysts are optimistic about the company’s preparations for an FDA meeting regarding accelerated approval and the publication of results expected in the second half of 2025 [2].

Vera Therapeutics continues to focus on expanding atacicept’s development across multiple autoimmune kidney diseases. The company's strong financial position, with a healthy current ratio of 27.68 and more cash than debt on its balance sheet, supports these ambitions [2].

Investors and patients alike are closely watching Vera Therapeutics' progress, with hopes that atacicept will become a new standard in IgAN therapy. The company's CEO, Marshall Fordyce, M.D., expressed optimism about atacicept’s potential to advance the standard of care for IgAN and the company’s readiness for a potential commercial launch in 2026 [3].

References:
[1] https://www.gurufocus.com/news/2901380/vera-therapeutics-vera-target-price-boosted-following-promising-study-results-vera-stock-news
[2] https://www.investing.com/news/analyst-ratings/evercore-isi-maintains-outperform-rating-on-vera-therapeutics-stock-93CH-4075475
[3] https://www.investing.com/news/stock-market-news/vera-therapeutics-shares-soar-on-positive-phase-3-trial-results-93CH-4075451